TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

PRECEDEX

DEXMEDETOMIDINE HYDROCHLORIDE
Approved 1999-12-17
4
Indications
--
Phase 3 Trials
1
Priority Reviews
26
Years on Market

Details

Status
Prescription
First Approved
1999-12-17
Routes
INJECTION
Dosage Forms
INJECTABLE

Companies

Active Ingredient: DEXMEDETOMIDINE HYDROCHLORIDE

PRECEDEX Approval History

Loading approval history...

What PRECEDEX Treats

1 indications

PRECEDEX is approved for 1 conditions since its original approval in 1999. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Sedation
Source: FDA Label
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

PRECEDEX FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

PRECEDEX is a alpha 2 -adrenergic receptor agonist indicated for: • Sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting. Administer PRECEDEX by continuous infusion not to exceed 24 hours. • Sedation of non-intubated adult patients prior to and/or during surgical and other procedures. • Sedation of non-intubated pediatric patients aged 1 month to less than 18 years prior to and during non-invasive procedures. 1.1 Intensive Care Unit Sedation PRECEDEX is indicated for sedation of initially intubated and mechanically ventilated ...

PRECEDEX Patents & Exclusivity

Latest Patent: Jul 2032

Patents (190 active)

US8455527*PED Expires Jul 4, 2032
US8242158*PED Expires Jul 4, 2032
US8338470*PED Expires Jul 4, 2032
US8648106*PED Expires Jul 4, 2032
US9320712*PED Expires Jul 4, 2032
US9616049*PED Expires Jul 4, 2032
US8455527 Expires Jan 4, 2032
US9616049 Expires Jan 4, 2032
US8242158 Expires Jan 4, 2032
US10016396 Expires Jan 4, 2032
+ 180 more patents
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.